JTT-130, [diethyl-2-({3-dimethylcarbamoyl-4-[(4′-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl }acetyloxymethyl)-2-phenylmalonate], a novel intestine-specific MTP inhibitor, was designed to be rapidly hydrolyzed and inactivated by the cleavage of the ester group in the structure immediately after intestinal absorption in order to avoid inhibition of hepatic MTP resulting in hepatic steatosis [12]. Here, MTTP is linked to fatty liver disease.